The London Company, an investment management company, released “The London Company Large Cap Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S. equities increased in the fourth quarter and most of the major indices saw positive gains. The quarter’s economic data was mixed but generally encouraging. The portfolio returned 0.8% (0.6% net) during the quarter compared to a 2.8% increase for the Russell 1000 Index. Positive sector exposure has contributed to offset the negative impact of stock selection on the relative performance. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2024.
In its fourth quarter 2024 investor letter, The London Company Large Cap Strategy emphasized stocks such as Bruker Corporation (NASDAQ:BRKR). Bruker Corporation (NASDAQ:BRKR) focuses on developing, manufacturing, and distributing scientific instruments, and analytical and diagnostic solutions. The one-month return of Bruker Corporation (NASDAQ:BRKR) was -5.87%, and its shares lost 41.04% of their value over the last 52 weeks. On February 25, 2025, Bruker Corporation (NASDAQ:BRKR) stock closed at $50.99 per share with a market capitalization of $7.73 billion.
The London Company Large Cap Strategy stated the following regarding Bruker Corporation (NASDAQ:BRKR) in its Q4 2024 investor letter:
“Initiated: Bruker Corporation (NASDAQ:BRKR) – BRKR designs and manufactures advanced scientific instruments as well as analytical and diagnostic solutions for a number of differentiated end markets in the life sciences arena. Its solutions enable its customers to explore life and materials at microscopic, molecular and cellular levels. With a global presence and a. focus on life sciences, it benefits from long-term drivers like proteomics research. BRKR derives its competitive moat from its highly innovative instruments that push the cutting edge of science, enabling strong pricing power and market leadership. BRKR’s management team has an excellent track record of capital allocation and delivering on their promises that help create shareholder value. Over time, BRKR has reduced its reliance on government/academic customers, diversified away from Europe, increased growth, and expanded margins meaningfully. BRKR also possesses many characteristics we look for in a company, including a strong balance sheet. high ROIC (>20%), improving margin (close to 20%), and high inside ownership. We already own BRKR in our the SMID and Mid Cap portfolios.”
A scientist in a laboratory wearing safety gear while operating a mass spectrometry machine.
Bruker Corporation (NASDAQ:BRKR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 34 hedge fund portfolios held Bruker Corporation (NASDAQ:BRKR) at the end of the fourth quarter compared to 31 in the third quarter. Bruker Corporation (NASDAQ:BRKR) reported revenues of $3.37 billion in the fiscal year 2024, representing a 13.6% increase compared to 2023. While we acknowledge the potential of Bruker Corporation (NASDAQ:BRKR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we discussed Bruker Corporation (NASDAQ:BRKR) and shared the list of best nanotechnology stocks to buy according to hedge funds. The London Company’s SMID Cap Strategy added Bruker Corporation (NASDAQ:BRKR) to its portfolio during Q2 2024. In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.